Josep Ramon Germa
Overview
Explore the profile of Josep Ramon Germa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
128
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Figueras A, Arbos M, Quiles M, Vinals F, Germa J, Capella G
BMC Cancer
. 2013 Mar;
13:125.
PMID: 23506169
Background: The malignant potential of tumour cells may be influenced by the molecular nature of KRAS mutations being codon 13 mutations less aggressive than codon 12 ones. Their metabolic profile...
2.
Pernas S, Gil-Gil M, Ochoa de Olza M, Guma A, Climent F, Petit A, et al.
Breast Cancer Res Treat
. 2012 Jul;
134(3):1161-8.
PMID: 22772380
One of the most efficacious primary therapies in HER2-positive breast cancer was published by the M.D. Anderson group in 2005. This randomized trial evaluated the addition of trastuzumab to a...
3.
Oaknin A, Barretina P, Perez X, Jimenez L, Velasco M, Alsina M, et al.
Int J Gynecol Cancer
. 2010 Feb;
20(1):87-91.
PMID: 20130507
Introduction: : In recurrent ovarian cancer, CA-125 could be the only objective response criteria. This study analyzes response patterns regarding CA-125 in responders versus nonresponders and determines whether a specific...
4.
Castillo-Avila W, Piulats J, Garcia Del Muro X, Vidal A, Condom E, Casanovas O, et al.
Clin Cancer Res
. 2009 May;
15(10):3384-95.
PMID: 19417025
Purpose: Germ cell tumors (GCT) of the testis are highly curable, but those patients who are refractory to cisplatin (CDDP)-based combination chemotherapy have a poor prognosis. Therefore, identifying new alternatives...
5.
Laquente B, Lacasa C, Ginesta M, Casanovas O, Figueras A, Galan M, et al.
Mol Cancer Ther
. 2008 Mar;
7(3):638-47.
PMID: 18347150
Gemcitabine shows a marked antitumor effect as a result of its cytotoxic action toward proliferative cells. In this article, we aim to investigate the potential antitumor and antiangiogenic effect of...
6.
Corral M, Clopes A, Navarro M, Germa J, Borras J
Med Clin (Barc)
. 2007 Aug;
129(4):134-6.
PMID: 17663967
Background And Objective: To assess the impact on the medicines budget of the introduction of new treatments in colorectal cancer, as monoclonal antibodies cetuximab and bevacizumab and oxaliplatin in the...
7.
Dotor E, Cuatrecases M, Martinez-Iniesta M, Navarro M, Vilardell F, Guino E, et al.
J Clin Oncol
. 2006 Apr;
24(10):1603-11.
PMID: 16575011
Purpose: The purpose of this study was to analyze the value of germline and tumor thymidylate synthase (TS) genotyping as a prognostic marker in a series of colorectal cancer patients...
8.
Gonzalez S, Blanco I, Campos O, Julia M, Reyes J, Llompart A, et al.
Cancer Genet Cytogenet
. 2005 Mar;
158(1):70-4.
PMID: 15771908
The incidence of familial adenomatous polyposis (FAP) is approximately 7.4 per 100,000 inhabitants. APC gene mutations have been found in 60-70% of all FAP families, codons 1309 (20%) and 1061...